Trial Name | Description |
BREAKWATER GI |
Dr. J. Lenehan An Open-Label, Multicenter, Randomized Phase 3 Study of First-Line Encorafenib plus Cetuximab with or without Chemotherapy versus Standard of Care Therapy with a Safety Lead-In of Encorafenib and Cetuximab plus Chemotherapy in Participants |
FORTITUDE 102 Gastric-GEJ |
Dr. M. Vincent A Phase 1B/3 Study of Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone in Subjects with Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer with FGFR2B Overexpression |
CHASe-PDAC |
Dr. J. Lenehan Not Open Yet - An open-label, single-arm, phase 1 study of the combination of FMT and gemcitabine with nab-paclitaxel as first-line therapy in patients with advanced pancreatic ductal adenocarcinoma. |